Printer Friendly

U.S DISTRICT COURT DECIDES IN FAVOR OF CISTRON IN PATENT INFRINGEMENT SUIT

 PINE BROOK, N.J., Sept. 27 /PRNewswire/ -- The U.S. District Court, District of New jersey, has granted Cistron Biotechnology, Inc.'s motion for a summary judgement against PeproTech, Inc. of Rocky Hill, N.J. in a patent infringement suit involving Interleukin-1 beta.
 In his decision, Judge Garrett E. Brown, Jr. concluded that the scope of the Interleukin-1 patent in question encompasses not only the full-length precursor of the IL-1b protein but the protein's fragments as well.
 Damages were not addressed in the court's summary judgement.
 Cistron indicated that it intends to continue to defend its IL-1 patent rights against infringement by others. Robert Hillman and Paul Clark of Fish & Richardson, Boston, represented the plaintiffs.
 Cistron, together with the New England Medical Center Hospitals, Inc., the trustees of Tufts College, Massachusetts Institute of Technology, and Wellesley College, filed suit against PeproTech in December, 1991, alleging infringement of U.S. Patent No. 4,766,069 "Recombinant DNA which Codes for Interleukin-1b," issued August, 1988, which the institutions own and to which Cistron is the exclusive licensee.
 Interleukin-1 is a key human immune system regulator produced by white blood cells which may have therapeutic applications in cancer, wound healing and vaccine adjuvents.
 Cistron's primary product area is immune response regulators known as lymphokines. The company manufactures and sells lymphokine assay kits to pharmaceutical companies, the government and academic institutions in the United States, Europe and the Far East for cancer, arthritis and other autoimmune disease research.
 -0- 9/27/93
 /CONTACT: Harold W. Smith of Hal Smith Associates, 201-305-0244/


CO: Cistron Biotechnology, Inc.; PeproTech, Inc. ST: New Jersey IN: MTC SU:

TS-SM -- NY018 -- 5799 09/27/93 09:01 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 27, 1993
Words:278
Previous Article:MFS ANNOUNCES TAMPA NETWORK; BRINGS U.S. TOTAL TO 16 METROPOLITAN AREAS
Next Article:IMMUNEX SEPSIS DRUG SHOWS NO CLINICAL BENEFIT
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters